non fda approved glp 1 GLP-1 use tripled among non-diabetics, reaching $5.8B in 2022 Compounding GLP-1 Drugs - Recent

This review highlights the dual need for innovation in formulation science to enhance the safety and efficacy of DHA-based products and for increased regulatory scrutiny and public education surrounding unapproved agents such as melanotan

And when you combine those [00:16:00] things with appropriate hormone thyroid care, we absolutely do not show that people gain their weight back after they discontinue

Exactly how GLP-1 medicines might protect against toxic protein build-up and dementia needs further investigation

The article describes rapid fluid shifts and fast weight loss during roughly the first four to eight weeks of therapy, which can transiently lower hemoglobin and protein levels

,

10.1016/S0166-4328(02)00286-3 24 DicksonS